This study elucidates the dual role of complement activation in the treatment of HER2-positive breast cancer, providing critical experimental evidence for designing combination strategies involving mCRP blockade or developing novel bispecific antibodies.
Literature Overview
This article, titled "Complement in HER2-Positive Breast Cancer: A Conditionally Protective Mechanism Under Attack," published in the journal Antibodies, systematically explores the complex mechanisms of the complement system in the treatment of HER2-positive breast cancer. The article points out that while the traditional view holds that the efficacy of anti-HER2 monoclonal antibodies primarily stems from ADCC, emerging evidence indicates that complement-dependent cytotoxicity (CDC) and complement-dependent cellular phagocytosis (CDCP) play a critical synergistic role in the combined therapy of trastuzumab and pertuzumab. The article reviews the molecular basis of complement activation, the mechanisms by which tumor cells evade killing via membrane-bound complement regulatory proteins (mCRPs), and the dual role of C1q in the tumor microenvironment.Background Knowledge
HER2-positive breast cancer is characterized by high invasiveness and a propensity for metastasis. Although targeted therapies have significantly improved prognosis, approximately 25% of patients still experience recurrence within 10 years. The primary challenge in current treatment lies in tumor cell resistance to CDC. This resistance mainly arises from the overexpression of mCRPs on the tumor cell surface, particularly CD55, CD59, and CD46, which inhibit the complement cascade and prevent the formation of the membrane attack complex (MAC). Furthermore, C1q, as the recognition molecule of the classical complement pathway, exhibits a unique conditionally protective role in HER2-positive breast cancer; it can initiate complement-mediated killing while also directly inhibiting tumor growth through non-complement pathways (such as activating WWOX). However, in other malignancies, C1q often promotes tumor progression. This context-dependency classifies HER2-positive breast cancer as a "conditionally complement-protected tumor," where treatment outcomes depend on the balance between antibody-mediated complement activation and mCRP-mediated escape.
Research Methods and Core Experiments
This article employs a narrative review approach, integrating original experimental studies, clinical cohorts, and clinical trial data from PubMed, Scopus, and Web of Science. The research focuses on analyzing the complement activation capabilities of trastuzumab and pertuzumab across different models. Key evidence includes: in SCID-beige mouse models, which lack adaptive immunity and NK cells, the anti-tumor effect of combination therapy remains significant, confirming the roles of CDC and CDCP; in vitro experiments demonstrated that the synergistic effect was eliminated by C1 inhibitor treatment or serum heat inactivation; in vivo, the efficacy of combination therapy disappeared in C1qa gene knockout mice. Additionally, the study analyzed the correlation between CD55 and CD59 expression levels and disease-free survival (DFS) in clinical cohorts, as well as the relationship between C1QA gene expression and overall survival (OS).Key Conclusions and Perspectives
Research Significance and Prospects
This discovery holds significant implications for drug development, suggesting that future HER2-targeted therapies should focus on optimizing complement activation capabilities, such as developing bispecific antibodies or combining them with mCRP blockers. In terms of clinical monitoring, detecting mCRP expression levels or C1q deposition in tumor tissue could serve as biomarkers to predict patient response to anti-HER2 therapy. Furthermore, this study emphasizes the need to consider the context-dependency of the complement system in disease modeling, particularly when constructing humanized mouse models for evaluating immunotherapies, ensuring complement system integrity to accurately reflect CDC mechanisms.
Conclusion
In summary, HER2-positive breast cancer is defined as a conditionally complement-protected tumor, where treatment success depends on the dynamic balance between antibody-mediated complement activation and tumor cell mCRP-mediated escape mechanisms. This study not only re-establishes the central role of CDC and CDCP in the combined treatment of trastuzumab and pertuzumab but also reveals the unique protective role of C1q in this disease. From a translational perspective, understanding this mechanism provides new avenues for overcoming therapeutic resistance, specifically by enhancing complement activation (e.g., using bispecific antibodies) or inhibiting escape mechanisms (e.g., targeting CD55/CD59) to improve patient prognosis. Future research needs to further quantify the relative contributions of CDC, CDCP, and ADCC, and develop standardized biomarkers to guide personalized therapy, thereby refining the comprehensive care system for HER2-positive breast cancer.
